Moderna
Moderna, Inc., commonly referred to as Moderna, is a pioneering biotechnology company headquartered in the United States. Founded in 2010, Moderna has rapidly established itself as a leader in the mRNA technology sector, focusing on the development of transformative medicines and vaccines. The company gained global recognition for its COVID-19 vaccine, which showcased the potential of mRNA technology in combating infectious diseases. With major operational regions across North America and Europe, Moderna's core products include vaccines and therapeutics targeting infectious diseases, autoimmune disorders, and cancer. The unique aspect of Moderna's approach lies in its innovative use of messenger RNA to instruct cells to produce proteins that can prevent or treat diseases. As a key player in the biotechnology industry, Moderna continues to push the boundaries of science, achieving significant milestones and contributing to public health advancements worldwide.
DitchCarbon Score
How does Moderna's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Moderna's score of 72 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Moderna's reported carbon emissions
In 2023, Moderna reported total carbon emissions of approximately 11,240,000 kg CO2e for Scope 1 and 4,310,000 kg CO2e for Scope 2, with a total Scope 2 emissions of about 11,506,000 kg CO2e when calculated on a location-based method. The company has set ambitious climate commitments, aiming for net-zero carbon emissions in Scopes 1 and 2 by 2030. This commitment is part of a broader strategy to achieve net-zero greenhouse gas emissions across its entire value chain by 2045. Moderna's near-term targets include a significant reduction of absolute Scope 1 and 2 greenhouse gas emissions by 90% from a 2021 baseline by 2030. Additionally, the company aims for 85% of its suppliers, covering purchased goods and services, capital goods, and upstream transportation and distribution, to have science-based targets by 2028. Long-term, Moderna commits to maintaining a minimum of 90% absolute reductions in Scopes 1 and 2 emissions from 2030 through 2045, alongside a 90% reduction in absolute Scope 3 emissions by 2045. These initiatives reflect Moderna's commitment to sustainability and its proactive approach to addressing climate change within the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 9,142,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 928,000 | 0,000,000 | 000,000 |
| Scope 3 | 489,508,000 | 0,000,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Moderna is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
